NRF2 deletion hinders the proliferation and metastasis of breast cancer cells by downregulating the cytoskeleton-binding GTPase RhoA while restoring RhoA counteracted growth and metastasis suppression in vitro. The gene discussed is NFE2L2; the disease is breast carcinoma.